MX2021008610A - Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. - Google Patents

Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.

Info

Publication number
MX2021008610A
MX2021008610A MX2021008610A MX2021008610A MX2021008610A MX 2021008610 A MX2021008610 A MX 2021008610A MX 2021008610 A MX2021008610 A MX 2021008610A MX 2021008610 A MX2021008610 A MX 2021008610A MX 2021008610 A MX2021008610 A MX 2021008610A
Authority
MX
Mexico
Prior art keywords
cancer
erk
combinations
subject
effects
Prior art date
Application number
MX2021008610A
Other languages
English (en)
Inventor
Saurabh Saha
Gary Decrescenzo
Dean Welsch
Jeffrey James Roix
Original Assignee
Biomed Valley Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc filed Critical Biomed Valley Discoveries Inc
Publication of MX2021008610A publication Critical patent/MX2021008610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención proporciona, inter alia, métodos de tratamiento o mejoramiento de los efectos de un cáncer en un sujeto. Los métodos incluyen administrar al sujeto una cantidad efectiva de (i) un primer agente 5 anticáncer, el cual es BVD-523 o una sal farmacéuticamente aceptable del mismo y (ii) un segundo agente anticáncer, el cual es un inhibidor de RAF del tipo 1 (como el debrafenib) u otro inhibidor de RAF (como regorafenib) o una sal farmacéuticamente aceptable de los mismos, para tratar o 10 mejorar los efectos del cáncer. También se proporcionan composiciones y kits farmacéuticos para tratar o mejorar los efectos de un cáncer en un sujeto.
MX2021008610A 2013-12-20 2014-12-19 Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. MX2021008610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919347P 2013-12-20 2013-12-20
PCT/US2014/071715 WO2015095819A2 (en) 2013-12-20 2014-12-19 Cancer treatment using combinations of erk and raf inhibitors

Publications (1)

Publication Number Publication Date
MX2021008610A true MX2021008610A (es) 2022-07-27

Family

ID=53403899

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008201A MX2016008201A (es) 2013-12-20 2014-12-19 Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2021008610A MX2021008610A (es) 2013-12-20 2014-12-19 Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016008201A MX2016008201A (es) 2013-12-20 2014-12-19 Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.

Country Status (11)

Country Link
US (1) US10668055B2 (es)
EP (2) EP4043017A1 (es)
JP (1) JP6678585B2 (es)
CN (1) CN106211755B (es)
AU (1) AU2014368906B2 (es)
BR (1) BR112016014481B1 (es)
CA (2) CA2934669C (es)
ES (1) ES2909910T3 (es)
MX (2) MX2016008201A (es)
RU (1) RU2722784C2 (es)
WO (1) WO2015095819A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
US20180369195A1 (en) * 2015-11-30 2018-12-27 The Regents Of The University Of California Combination therapy for treatment of melanoma
CN109069646A (zh) * 2016-02-05 2018-12-21 埃沃尔科学有限责任公司 治疗癌症的组合
WO2017158621A1 (en) * 2016-03-14 2017-09-21 Sphaera Pharma Pvt. Ltd. Trigonelline based compounds
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
US10973829B2 (en) * 2016-09-19 2021-04-13 Novartis Ag Therapeutic uses of a C-RAF inhibitor
MX2019008458A (es) 2017-01-17 2019-12-02 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
AU2018269982A1 (en) * 2017-05-16 2020-01-02 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
WO2018226802A1 (en) * 2017-06-06 2018-12-13 The Johns Hopkins University Induction of synthetic lethality with epigenetic therapy
EP3664851A4 (en) 2017-08-07 2021-05-19 Evol Science LLC COMBINATIONS FOR TREATING CANCER
JP7332589B2 (ja) * 2017-10-12 2023-08-23 ノバルティス アーゲー 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
KR20200086305A (ko) * 2017-11-20 2020-07-16 톨레모 테라퓨틱스 아게 진단 방법
WO2019103984A1 (en) * 2017-11-22 2019-05-31 Memorial Sloan Kettering Cancer Center Compositions including fatp1, fatp3, fatp4, fatp5, and/or fatp6 inhibitors and uses thereof
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3211167A1 (en) * 2021-02-19 2022-08-25 Samuel C. BLACKMAN Combination of raf inhibitor and mek inhibitor
CN113018269B (zh) * 2021-03-14 2022-06-03 华中科技大学同济医学院附属协和医院 复合颗粒物、其制备方法及其应用
WO2023076991A1 (en) * 2021-10-28 2023-05-04 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2023081676A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
CN115400122B (zh) * 2022-04-29 2023-04-18 佛山病原微生物研究院 一种tak-632在制备用于抗腺病毒感染的药物中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2158642A1 (en) 1993-03-19 1994-09-29 Hubert Koster Dna sequencing by mass spectrometry via exonuclease degradation
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
EP3943489A1 (en) 2004-05-14 2022-01-26 Vertex Pharmaceuticals Incorporated Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
JP2008545670A (ja) 2005-05-27 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 疾患を処置するためのジアリールウレア類を含む組合せ治療
CN102603581B (zh) * 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
MX2009013333A (es) * 2007-06-05 2010-01-18 Schering Corp Derivados de indazol policiclicos y su uso como inhibidores de erk para el tratamiento de cancer.
US8288520B2 (en) 2008-10-27 2012-10-16 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and system
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
EP2640860A4 (en) 2010-11-19 2014-06-04 Univ California COMPOSITIONS AND METHODS FOR DETECTING AND TREATING B-RAF HEMMER RESISTANT MELANOMES
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
EP2780010A1 (en) * 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors

Also Published As

Publication number Publication date
AU2014368906B2 (en) 2020-04-30
EP4043017A1 (en) 2022-08-17
EP3082800A2 (en) 2016-10-26
AU2014368906A1 (en) 2016-07-21
ES2909910T3 (es) 2022-05-10
CN106211755B (zh) 2021-06-22
BR112016014481A2 (pt) 2018-02-20
CA2934669A1 (en) 2015-06-25
US20160310476A1 (en) 2016-10-27
EP3082800A4 (en) 2017-07-05
WO2015095819A2 (en) 2015-06-25
BR112016014481B1 (pt) 2022-11-08
RU2722784C2 (ru) 2020-06-03
JP2017502017A (ja) 2017-01-19
CN106211755A (zh) 2016-12-07
JP6678585B2 (ja) 2020-04-22
CA2934669C (en) 2022-10-04
EP3082800B1 (en) 2022-02-02
WO2015095819A3 (en) 2015-08-13
MX2016008201A (es) 2017-04-27
CA3168002A1 (en) 2015-06-25
US10668055B2 (en) 2020-06-02
RU2016129287A (ru) 2018-01-23

Similar Documents

Publication Publication Date Title
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
PH12016502352A1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
NZ757538A (en) Reducing beta-catenin expression to potentiate immunotherapy
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer